Holen Sie sich die Stockscreener-App
2.02
5.76%
0.11
Handel nachbörslich:
2.06
0.04
+1.98%
Schlusskurs vom Vortag:
$1.91
Offen:
$1.93
24-Stunden-Volumen:
248.66K
Relative Volume:
0.82
Marktkapitalisierung:
$212.53M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-5.3326
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-1.94%
1M Leistung:
-12.93%
6M Leistung:
-11.01%
1J Leistung:
+0.50%
1-Tages-Spanne:
$1.92
$2.085
1-Wochen-Bereich:
$1.80
$2.19
52-Wochen-Spanne:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.02 | 201.21M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-29 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
How to build a dashboard for ProQR Therapeutics N.V. stock2025 Macro Impact & Fast Entry Momentum Alerts - Newser
How to track smart money flows in ProQR Therapeutics N.V.Bear Alert & Community Consensus Picks - Newser
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Chardan Capital - MarketBeat
ProQR Therapeutics N.V. stock outlook for YEARIndex Update & AI Driven Stock Movement Reports - Newser
Is ProQR Therapeutics N.V. stock entering bullish territory2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
Published on: 2025-08-13 02:06:12 - Newser
How high can ProQR Therapeutics N.V. stock goShare Buyback & Technical Entry and Exit Tips - Newser
How to track smart money flows in ProQR Therapeutics N.V. [2025 AllTime Highs]Free Community Verified Trade Signals - Newser
Real time breakdown of ProQR Therapeutics N.V. stock performanceInsider Selling & Intraday High Probability Alerts - Newser
Can ProQR Therapeutics N.V. recover in the next quarter2025 Price Action Summary & Long-Term Growth Plans - Newser
How to forecast ProQR Therapeutics N.V. trends using time seriesMomentum Prediction Based on AI Backtesting - Newser
What to do if you’re stuck in ProQR Therapeutics N.V.Share Buyback & Real-Time Buy Signal Notifications - Newser
Is ProQR Therapeutics N.V. stock a growth or value playMarket Performance Recap & Consistent Profit Alerts - Newser
Buy Signal for ProQR Therapeutics N.V. Stock Key Technical Indicators to WatchFree Confirmed Setup With Expert Accuracy - Newser
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving AverageShould You Sell? - MarketBeat
Using economic indicators to assess ProQR Therapeutics N.V. potentialFree Technical Entry Strategy for Beginners - Newser
Volume spikes in ProQR Therapeutics N.V. stock – what they meanSummary of Trade Cycles in 5-Year Range - Newser
ProQR's Strategic Advancements and Clinical Prospects Drive Buy Rating with $12 Price Target - AInvest
Statistical indicators supporting ProQR Therapeutics N.V.’s strengthFree Smart Allocation Stock Pick Insights - Newser
Live market analysis of ProQR Therapeutics N.V.Safe Momentum Strategy With Trend Analysis - Newser
Published on: 2025-08-10 23:41:36 - Newser
Using Ichimoku Cloud for ProQR Therapeutics N.V. technicalsFree Price Action Based Buy Opportunity List - Newser
Ranking ProQR Therapeutics N.V. among high performing stocks via toolsTechnical Safety Zone Pattern Recognition - Newser
Real time alert setup for ProQR Therapeutics N.V. performanceSector Rotation Strategy for Smart Traders - Newser
ProQR Therapeutics (PRQR) to Release Earnings on Thursday - MarketBeat
ProQR Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Analyzing ProQR Therapeutics N.V. with risk reward ratio chartsFree Swing Trading Entry Point Signals - Newser
ProQR: Q2 Earnings Snapshot - Manistee News Advocate
How institutional ownership impacts ProQR Therapeutics N.V. stockFree Breakout Momentum Picks With Protection - Newser
ProQR Therapeutics shares rise 3.17% intraday after reporting a Q2 loss of $13.8 million, missing Wall Street expectations. - AInvest
ProQR Therapeutics Reports Q2 Earnings: $13.8mln Loss, $4.3mln Revenue - AInvest
Published on: 2025-08-08 07:28:56 - Newser
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Therapeutics NV earnings missed by €0.04, revenue fell short of estimates - Investing.com
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):